Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Stock Investor Wire

RLFTF Quote, Trading Chart, Mondobiotech Holding AG Basel


home / stock / rlftf / rlftf quote

$0.3582 Last:

-1.86% Change Percent:

$0.359 Open:

$0.3582 Previous Close:

$0.393 High:

$0.34 Low:

8,531,040 Volume:

02/26/2021 04:54:46 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Last Five Trading Days

Stock DateOpen PriceClose PriceHighLowVolume
2021-02-260.3590.35820.3930.348,531,040
2021-02-250.39970.3650.39990.3511,564,273
2021-02-240.40750.38930.4150.382522,325,799
2021-02-230.36990.4240.49990.33846,804,690
2021-02-220.40250.36980.4110.3657,806,284
2021-02-190.340.40180.4050.3413,022,724
2021-02-180.3633040.35170.36990.35015,452,526
2021-02-170.362040.36210.36980.35515,828,946
2021-02-160.394880.360.39490.359,414,658
2021-02-150.370.35020.370.33412,643,651
2021-02-120.370.35020.370.33412,643,651
2021-02-110.3767280.3580.38460.350516,401,714
2021-02-100.4150.3840.4150.36820,797,773
2021-02-090.4344840.3790.450.31104,251,465
2021-02-080.590.650.70.5724,391,855
2021-02-050.50.53150.5790.57,957,133
2021-02-040.560.520.560.51037,663,727
2021-02-030.540.5240.540.49513,426,341
2021-02-020.5730.5380.5730.52910,570,360
2021-02-010.5579680.56490.59750.52517,240,720
Stock Information

Mondobiotech Holding AG Basel Company Name:

RLFTF Stock Symbol:

OTC Market:

Mondobiotech Holding AG Basel Website:

MENU
RLFTF RLFTF Quote RLFTF Short RLFTF News RLFTF Articles RLFTF Message Board
Get RLFTF Alerts

News, Short Squeeze, Breakout and More Instantly...

Stock Investor Wire
RECENT RLFTF NEWS
  • RLFTF - NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint

    GENEVA, SWITZERLAND / ACCESSWIRE / February 24, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development, announces that NeuroRx, Inc. has reported...

  • RLFTF - NeuroRx Announces that ZYESAMI(TM) (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

    NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint NeuroRx to File for Emergency Use Authori...

  • RLFTF - NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI(TM) (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19

    NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19 If Authorized for Use, ZYESAMI™ Would be First Treatment Specifical...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.


Sign up or login to continue

Sign up or login to continue.


Forgot password?




WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News